Our client was a global pharma company with assets in multiple rare diseases. They had a need to enhance reputation among and support from Patient Advocacy Groups (PAGs) and create a global and cross disease area approach.
CRA approach
- Internal and external research to understand and validate drivers of effective collaboration and how the company is perceived by PAGs
- Characterization of rare disease markets to enable PAG planning regardless of DA or geography
- Identification and response to internal challenges
- Reference to best practice analogs of advocacy in rare diseases
- Deployment of IMPETUS for stakeholder planning
Client impact
- Market independent strategy for planning PAG engagement across all disease areas and geographies
- Market archetypes defined for Rare Diseases
- Practical playbook as basis for individual market planning
- Cross functional internal alignment
- Roll out for specific Rare Diseases in selected markets